Literature DB >> 16014573

Block of delayed-rectifier potassium channels by reduced haloperidol and related compounds in mouse cortical neurons.

Shi-Bing Yang1, Felix Major, Lutz F Tietze, Marjan Rupnik.   

Abstract

Haloperidol is known as an antagonist of dopamine D2 receptors. However, it also blocks a variety of ion channels at concentrations above the therapeutic range. Reduced haloperidol (R-haloperidol), one of the main metabolites of haloperidol, has been reported to accumulate in certain tissues, particularly in brain cortex, and it may produce the pharmacological effects associated with haloperidol treatment. In this study, we assessed the effect of R-haloperidol and other related compounds on native delayed-rectifier potassium channels (K(DR)) in mouse cortical neurons by using the whole-cell patch-clamp technique. Although R-haloperidol has much lower affinity to D2 receptors than haloperidol, the IC50 of R-haloperidol to block K(DR) currents was 4.4 microM, similar to its parent compound. The binding site of R-haloperidol is on the cytoplasmic side of the channel because its quaternary derivative preferentially inhibited the currents from intracellular side. 4-Chlorophenyl-4-hydroxypiperidine (4C4HP) is the active fragment of haloperidol because other compounds containing this moiety, including L-741,626 (3-[4-(4-chlorophenyl)-4-hydroxypiperidin-L-yl]-methyl-1H-indole) and loperamide, also blocked K(DR) channels. The potency of the 4C4HP fragment positively correlated with the hydrophobicity index (clogP) of the compounds tested. We conclude that R-haloperidol is a K(DR) channel blocker, although it does not interfere with the normal channel function at a clinically relevant concentration.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16014573     DOI: 10.1124/jpet.105.086561

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  1 in total

1.  Ventricular Tachycardia Triggered by Loperamide and Famotidine Abuse.

Authors:  Timothy R Larsen; Jedediah McMunn; Hala Ahmad; Soufian T AlMahameed
Journal:  Drug Saf Case Rep       Date:  2018-02-17
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.